“Against the backdrop of these statistics, Sanofi continues in its efforts to make insulin pens more affordable and accessible, and our aim is to improve the quality of life and healthcare ...

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY.Similar to Lilly, Sanofi also said it is ...

According to MSF, a prefilled human insulin pen could be sold at a profit at an estimated generic target price of just $0.94. The estimate informed the call for Lilly, Novo, Sanofi and other ...

Pens can contain 300 to 900 units of insulin, depending on the device and the insulin concentration. The standard concentration is 100 units per milliliter (mL) of insulin, known as U-100, though ...

Sanofi is cutting the list price of Lantus, ... (BD) needle on a Novo Nordisk Inc. NovoLog brand insulin pen in a posed photograph in New York on Friday, April 5, 2019.

Sanofi said that since May last year, the Department of Health had faced insulin pen rationing, as the previous sole supplier opted not to tender. It said nearly 50% of the insulin required for ...

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday ...

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday ...